Direx Group Morenova LISWT system is can address women's and men's sexual health.

Women's sexual health:

The next-generation trans-vaginal large-area shockwave therapy (LISWT) designed to enhance and restore proper functioning for women of every age.

Morenova LISWT Shockwave Treatment Applications for women:

Female Sexual Dysfunction

FSDStress Urinary Incontinenece

SUI Vulvodynia

Men's sexual health:

System is also used for ED. The world's best erectile dysfunction machine with proven results. Using two separate transducers., you get two functions for the price of 1!

What are the benefits / advantages of the Direx MoreNova system for ED (erectile dysfunction) LISWT men's sexual wellness?:

1. No manual holding of the shaft or applicator - no operator needed for treatment once it starts, therefore no operator fatigue or labor.

2. Treatment area is 50mm long and applies shockwaves simultaneously to both the left and right corpora - Large surface area completes a full treatment in a fraction of the time.

3. Dual Linear Shockwave Therapy - Proven to create angiogenesis

4. Short protocol of just 6 weeks.

The MoreNova is proven technology and risk free with no pain or side effects. This is a new/demo unit that has never been used! Zero pulses. Retail on this device is $29,995.

Reason for sale: We are moving away from equipment and focusing on consumable markets such as exosomes, enzymes, etc.

Lots of clinical studies for both women and men.

Custom crate included and will ship anywhere in the world. We can do a live call to show you the system. System ships from Los Alamitos, CA. Price $18,000 plus shipping.

This is the most technologically advanced low intensity shockwave therapy system for ED or erectile dysfunction. They have a patented linear transducer which has the larges surface area in the market to treat the most tissue, consistently in the least amount of time.

Interested? Give us a call or DM us.

The MoreNova device can be an excellent alternative to patients that were unresponsive to oral PDE5 inhibitors.